2. Search Result
Search Result
Results for "

reversal

" in MedChemExpress (MCE) Product Catalog:

55

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

8

Natural
Products

3

Isotope-Labeled Compounds

1

Antibodies

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0079
    Sugammadex sodium

    Org25969

    		 Drug Derivative Cardiovascular Disease Neurological Disease Cancer
    Sugammadex sodium is a synthetic γ-cyclodextrin derivative, and acts as a reversal agent for neuromuscular block. Sugammadex sodium shows nephroprotective effect in ischemia-reperfusion injury .
    Sugammadex sodium
  • HY-W587796
    6-Phosphoglucono-δ-lactone

    6-PGδL; 6-Phosphonoglucono-D-lactone

    		 Endogenous Metabolite PDI Cardiovascular Disease Metabolic Disease Cancer
    6-Phosphoglucono-δ-lactone (6-PGδL) is a reversal substrate of glucose-6-phosphate dehydrogenase (G6PD). 6-Phosphoglucono-δ-lactone is an intermediate compound in the oxidative branch of the pentose phosphate pathway (PPP). 6-Phosphoglucono-δ-lactone produced from D-glucose-6-phosphate by glucose-6-phosphate dehydrogenase (G6PDH) and is converted to 6-phosphoglutonate by lactonase. 6-Phosphoglucono-δ-lactone can be used for heart failure, type 2 diabetes and cancers research .
    6-Phosphoglucono-δ-lactone
  • HY-159818
    Amogammadex

    		Others Others
    Amogammadex is a reversal agent for rocuronium and vecuronium .
    Amogammadex
  • HY-108739
    Idarucizumab

    BI 655075

    		 Thrombin Cardiovascular Disease
    Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
    Idarucizumab
  • HY-B0079A
    Sugammadex

    Org25969 free acid

    		 Drug Derivative Cardiovascular Disease Neurological Disease Cancer
    Sugammadex is a synthetic γ-cyclodextrin derivative, and acts as a reversal agent for neuromuscular block. Sugammadex shows nephroprotective effect in ischemia-reperfusion injury .
    Sugammadex
  • HY-144366
    P-gp inhibitor 3

    		P-glycoprotein Cancer
    P-gp inhibitor 3 is an effective P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel .
    P-gp inhibitor 3
  • HY-153835
    Pegnivacogin

    		Factor Xa Others
    Pegnivacogin is a novel RNA-aptamer based factor IXa inhibitor featuring a reversal agent, anivamersen.
    Pegnivacogin
  • HY-153835A
    Pegnivacogin sodium

    		Factor Xa Others
    Pegnivacogin sodium is a novel RNA-aptamer based factor IXa inhibitor featuring a reversal agent, anivamersen.
    Pegnivacogin sodium
  • HY-109796
    NIK250

    		Bacterial Infection
    NIK250 is a potent multiple drug resistance (MDR) reversal agent that inhibits P-glycoprotein .
    NIK250
  • HY-161645
    P-gp modulator-4

    		P-glycoprotein Cancer
    P-gp modulator-4 (compound 4c) inhibits the efflux function of P-glycoprotein (P-gp). P-gp modulator-4 shows multidrug resistance (MDR) in cancer reversal activity (IC50 of Paclitaxel (HY-B0015) = 8.80, reversal fold = 211.8) .
    P-gp modulator-4
  • HY-113306
    1-Methyladenine

    		Endogenous Metabolite Others
    1-Methyladenine is a product of alkylation damage in DNA which can be repaired by damage reversal by oxidative demethylation.
    1-Methyladenine
  • HY-149809
    AcrB-IN-1

    		Bacterial Infection
    AcrB-IN-1 (Compound H6) is a potent AcrB inhibitor. AcrB-IN-1 can be used for the reversal of bacterial multidrug resistance .
    AcrB-IN-1
  • HY-106753
    Tolnapersine

    		P-glycoprotein Others
    Tolnapersine exhibits multidrug resistance (MDR) reversal activity, which reverses the resistance of tumor cells to multiple chemotherapy drugs by affecting P-glycoprotein (Pgp) on the cell membrane .
    Tolnapersine
  • HY-149360
    P-gb-IN-1

    		P-glycoprotein Cancer
    P-gb-IN-1 (compound Ⅲ-8), a 2,5-disubstituted furan derivative, is a highly effective, broadspectrum P-glycoprotein (P-gp) inhibitor. P-gb-IN-1 displayed the reversal activity by inhibiting P-gp efflux. P-gb-IN-1 has a potent affinity to P-gp by forming H-bond interactions with residues Asn 721 and Met 986. P-gb-IN-1 possesses broad-spectrum reversal activity and low toxicity in MCF-7/ADR cells .
    P-gb-IN-1
  • HY-123538
    GRK2 Inhibitor 1

    		Dopamine Receptor G Protein-coupled Receptor Kinase (GRK) Cardiovascular Disease
    GRK2 Inhibitor 1 (methyl 5-[2-(5-nitro-2-furyl)vinyl]-2-furoate) is a dual GRK2/β-ARK1 inhibitor that induces dopamine (DA) inhibition reversal (DIR). GRK2 Inhibitor 1 can also block serotonin-induced or neurotensin-induced DIR reversal. Note: DIR refers to the phenomenon in which neurons in addiction-related brain pathways become less sensitive to DA inhibition when exposed to moderate concentrations of DA for a long time .
    GRK2 Inhibitor 1
  • HY-175838
    P-gp-IN-32

    		P-glycoprotein Cancer
    P-gp-IN-32 is a P-glycoprotein (P-gp) inhibitor. P-gp-IN-32 exhibits low cytotoxicity and potent multidrug resistance (MDR) reversal activity against Doxorubicin (HY-15142A) in MCF7/ADR cells (IC50 = 0.11 μM, reversal fold (RF) = 215.9). P-gp-IN-32 can bind to P-gp directly, induce a conformation change of P-gp and inhibit the efflux function. P-gp-IN-32 can be used for the research of cancer, such as breast cancer .
    P-gp-IN-32
  • HY-116529
    Lamellarin E

    		Others Others
    Lamellarin E is a biologically active marine alkaloid, while the Lamellarin series of alkaloids show potential cytotoxicity, topoisomerase I inhibition, protein kinase inhibition, multidrug resistance reversal, and anti-HIV-1 activity .
    Lamellarin E
  • HY-153836A
    Anivamersen sodium

    		Factor Xa Others
    Anivamersen sodium is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
    Anivamersen sodium
  • HY-153836
    Anivamersen

    		Factor Xa Others
    Anivamersen is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
    Anivamersen
  • HY-18660B
    Ciraparantag acetate

    PER977 acetate

    		 Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag (PER977) acetate is a thrombin and factor Xa inhibitor. Ciraparantag acetate is a broad-spectrum reversal agent for anticoagulants, including low molecular weight heparins, unfractionated heparins, and some direct oral anticoagulants, but not VKAs .
    Ciraparantag acetate
  • HY-N1514
    Ganoderenic acid B

    		P-glycoprotein Cancer
    Ganoderenic acid B is a lanostane-type triterpene isolated from Ganoderma lucidum. Ganoderenic acid B exhibits potent reversal effect on ABCB1-mediated multidrug resistance of HepG2/ADM cells to Doxorubicin .
    Ganoderenic acid B
  • HY-N12101
    Anti-inflammatory agent 57

    		Others Inflammation/Immunology
    Anti-inflammatory agent 57 (Compound 13), pyranocoumarin, is a nature product. Anti-inflammatory agent 57 can be isolated from the roots of Peucedanum praeruptorum. Anti-inflammatory agent 57 has multidrug-resistance (MDR) reversal and anti-inflammatory effect .
    Anti-inflammatory agent 57
  • HY-162369
    PID-9

    		P-glycoprotein Cancer
    PID-9 is a P-glycoprotein inhibitor. PID-9 has multidrug resistance (MDR) reversal activity (IC50 = 0.1338 μM) and low toxicity. PID-9 inhibits the transport function of P-gp without downregulating P-gp expression .
    PID-9
  • HY-118706
    PD 118440

    		Dopamine Receptor Neurological Disease
    PD 118440 is an orally active dopamine (DA) agonist. PD 118440 has significant central nervous system effects, including inhibition of striatal DA synthesis, suppression of DA neuron firing, and reversal of Reserpine (HY-N0480)-induced depression in rats .
    PD 118440
  • HY-18660
    Ciraparantag

    PER977

    		 Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag (PER977) is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
    Ciraparantag
  • HY-163666
    HIV-1 inhibitor-68

    		HIV PKC Infection
    HIV-1 inhibitor-68 (compound 26) is a protein kinase C (PKC) activator derivative with reversal activity in HIV-1 latency. HIV-1 inhibitor-68 may be able to eliminate cells latently infected with HIV-1, .
    HIV-1 inhibitor-68
  • HY-101337
    Imiloxan

    RS 21361 free base

    		 Adrenergic Receptor Inflammation/Immunology
    Imiloxan (RS 21361) is a potent and selective alpha 2B-adrenoceptor antagonist. Imiloxan produces a dose-related reversal of Guanoxabenz (HY-U00123)-induced maximal mydriasis in male rats. Imiloxan has the potential for acute kidney injury research .
    Imiloxan
  • HY-101337A
    Imiloxan hydrochloride

    RS 21361

    		 Adrenergic Receptor Metabolic Disease
    Imiloxan (RS 21361) hydrochloride is a potent and selective alpha 2B-adrenoceptor antagonist. Imiloxan hydrochloride produces a dose-related reversal of Guanoxabenz (HY-U00123)-induced maximal mydriasis in male rats. Imiloxan hydrochloride has the potential for acute kidney injury research .
    Imiloxan hydrochloride
  • HY-122445
    Resorcinolnaphthalein
    2 Publications Verification

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease Inflammation/Immunology
    Resorcinolnaphthalein is a specific angiotensin-converting enzyme 2 (ACE2) enhancer and activates ACE2 activity with an EC50 value of 19.5 μM. Resorcinolnaphthalein can be used for the investigation of hypertension and renal fibrosis .
    Resorcinolnaphthalein
  • HY-18660A
    Ciraparantag TFA

    PER977 TFA

    		 Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag (PER977) TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
    Ciraparantag TFA
  • HY-123384
    KR30031

    		P-glycoprotein Cardiovascular Disease Cancer
    KR30031, a Verapamil (HY-14275) analog, is an orally active P-glycoprotein (P-gp) inhibitor. KR30031 enhances the cytotoxicity of anticancer agents by inhibiting P-gp with fewer cardiovascular adverse effects. KR30031 can be used to study multidrug resistance (MDR) reversal in cancer .
    KR30031
  • HY-149053
    OY-101

    		P-glycoprotein Cancer
    OY-101 is an orally active, potent and specific P-glycoprotein (P-gp) inhibitor. OY-101 can sensitize drug-resistant tumors and effectively reverse tumor multidrug resistance. OY-101 is improvements in water-solubility, cytotoxicity, and reversal activity compared to Tetrandrine (HY-13764) .
    OY-101
  • HY-159085
    P-gp inhibitor 24

    		P-glycoprotein Cancer
    P-gp inhibitor 24 (Compound 10) is an inhibitor for P-glycoprotein (P-gp)), that inhibits the P-gp mediated fluorescent dye efflux. P-gp inhibitor 24 exhibits multidrug resistance (MDR) reversal effect, enhances the cytotoxicity of Vincristine (HY-N0488) and Etoposide (HY-13629) in cancer cells .
    P-gp inhibitor 24
  • HY-121247
    Bromotetrandrine

    5-Bromotetrandrine; BrTet; W198

    		 P-glycoprotein Drug Derivative Cancer
    Bromotetrandrine is a potent inhibitor of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). Bromotetrandrine shows significant MDR reversal activity in vitro and in vivo, which may be related to the inhibition of P-gp overexpression and the increase in intracellular accumulation of anticancer agents. Bromotetrandrine is a brominated derivative of tetrandrine, which is promising for MDR modulator for tumor assessment .
    Bromotetrandrine
  • HY-P5391
    LL-37(17-32)

    		Bacterial Others
    LL-37(17-32) is a biological active peptide. (This peptide is an active segment of LL-37, a peptide derived from the C-terminal domain of human cathelicidin antimicrobial peptide. It has been reported that the LL17-32 peptide exhibits reversal effect on ABCG2-mediated multidrug resistance in cancer cell lines.)
    LL-37(17-32)
  • HY-14946
    Amifampridine

    3,4-Diaminopyridine

    		 Potassium Channel Neurological Disease
    Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB). Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs). Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .
    Amifampridine
  • HY-14946A
    Amifampridine phosphate

    3,4-Diaminopyridine phosphate

    		 Potassium Channel Neurological Disease
    Amifampridine (3,4-Diaminopyridine) phosphate is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB). Amifampridine phosphate is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine phosphate increases transmitter release from neuromuscular junctions (NMJs). Amifampridine phosphate can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .
    Amifampridine phosphate
  • HY-144393
    P-gp/BCRP-IN-1

    		BCRP Cancer
    P-gp/BCRP-IN-1 (compound 19) is a potential, relatively safe, orally active and efficient efflux transporter (P-gp and BCRP) inhibitor. P-gp/BCRP-IN-1 exerts resistance reversal by inhibiting the efflux function of P-gp and BCRP. P-gp/BCRP-IN-1 can overcome the resistance and improve the oral bioavailability of PTX (Paclitaxel) .
    P-gp/BCRP-IN-1
  • HY-16689
    VU 0240551
    1 Publications Verification

    		 Potassium Channel Others
    VU 0240551 is a potent neuronal K-Cl cotransporter KCC2 inhibitor (IC50=560 nM) and is selective versus NKCC1. VU 0240551 also inhibits hERG and L-type Ca 2+ channels. VU 0240551 attenuates GABA-induced hyperpolarization of P cells, produces a positive shift in the P cell GABA reversal potential and enhances P cell synaptic transmission .
    VU 0240551
  • HY-18660S
    Ciraparantag-d8 (tetra(hydrochloride) diacetate)

    PER977-d8 tetrahydrochloride diacetate

    		 Isotope-Labeled Compounds Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag-d8 (PER977-d8) tetrahydrochloride diacetate is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
    Ciraparantag-d8 (tetra(hydrochloride) diacetate)
  • HY-W035709
    Hydrocinchonine

    Dihydrocinchonine

    		 P-glycoprotein Apoptosis Cancer
    Hydrocinchonine (Dihydrocinchonine) is a multidrug resistance (MDR)-reversal agent. Hydrocinchonine directly inhibits the function and expression of P-gp, which is the mechanism by which it reverses MDR. Hydrocinchonine exerts synergistic apoptotic effect with Paclitaxel (HY-B0015) in MES-SA/DX5 cells. Hydrocinchonine can be used for the study of gynecological malignant tumors (such as uterine sarcoma) with drug resistance caused by excessive expression of P-gp .
    Hydrocinchonine
  • HY-W722107
    Timonacic-d4

    1,3-Thiazolidine-4-carboxylic acid-d4

    		 Isotope-Labeled Compounds Amino Acid Derivatives Cardiovascular Disease Cancer
    Timonacic-d4 (1,3-Thiazolidine-4-carboxylic acid-d4) is deuterium labeled Timonacic. Timonacic (1,3-Thiazolidine-4-carboxylic acid) is a thiol antioxidant. Timonacic has anti-aging and anti-hepatotoxic effects, and it can be used to study acute illnesses and liver diseases, by inducing reversal, it is also used in research on certain cancer cases .
    Timonacic-d4
  • HY-W002097R
    1-(5-Methylthiophen-2-yl)ethan-1-one (Standard)

    2-Acetyl-5-methylthiophene (Standard)

    		 Reference Standards Others Others
    Amifampridine (Standard) is the analytical standard of Amifampridine. This product is intended for research and analytical applications. Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB). Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs). Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .
    1-(5-Methylthiophen-2-yl)ethan-1-one (Standard)
  • HY-110152
    LSN2463359

    		mGluR Neurological Disease
    LSN2463359 is positive allosteric modulator of metabotropic glutamate 5 (mGlu5). LSN2463359 attenuates aspects of the behavioral response to administration of the competitive NMDA receptor antagonist. LSN2463359 selectively attenuates reversal learning deficits observed in the neurodevelopmental MAM E17 model . LSN2463359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    LSN2463359
  • HY-14946R
    Amifampridine (Standard)

    3,4-Diaminopyridine (Standard)

    		 Reference Standards Potassium Channel Neurological Disease
    Amifampridine (Standard) is the analytical standard of Amifampridine. This product is intended for research and analytical applications. Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB). Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs). Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .
    Amifampridine (Standard)
  • HY-135599
    Lysine hydroxamate

    		Bacterial Infection
    Lysine hydroxamate is an amino acid hydroxamate that inhibits the growth of Escherichia coli K-12. Of the other amino acid hydroxamates tested, only L-lysine hydroxamate reduced the growth rate. The inhibition of growth by L-serine hydroxamate could be rapidly reversed by adding L-serine to the bacterial culture or by removing the analog by filtration. This reversal was specific for L-serine. L-alanine, glycine, or adenine had no effect on the inhibited culture. There was no evidence for active transport of the analog.
    Lysine hydroxamate
  • HY-114268
    BRD-K98645985
    3 Publications Verification

    		 HIV Infection
    BRD-K98645985 is a BAF (mammalian SWI/SNF) transcriptional repression inhibitor with an EC50 of ~2.37 μM. BRD-K98645985 binds ARID1A-specific BAF complexes, prevents nucleosomal positioning, and potently reverses HIV-1 latency, without T cell activation or toxicity .
    BRD-K98645985
  • HY-14946S
    Amifampridine-d3

    3,4-Diaminopyridine-d3

    		 Isotope-Labeled Compounds Potassium Channel Neurological Disease
    Amifampridine-d3 (3,4-Diaminopyridine-d3) is deuterium labeled Amifampridine. Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB). Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs). Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .
    Amifampridine-d3
  • HY-123744
    PD-156707

    		Endothelin Receptor Cardiovascular Disease
    PD-156707 is an orally active, nonpeptide and selective Endothelin-A receptor antagonist. PD-156707 binds to human ET-A and ET-B receptors with Ki values of 0.17 nM and 133.8 nM, respectively. PD-156707 shows reversal of established chronic hypoxic pulmonary hypertension in rats. PD-156707 can be used for the study of diseases associated with abnormal ET-A receptor activation, particularly pulmonary hypertension, stroke, and heart failure .
    PD-156707
  • HY-13764A
    dl-Tetrandrine

    		Calcium Channel Cardiovascular Disease Inflammation/Immunology Cancer
    dl-Tetrandrine is an orally active and brain-penetrant calcium channel blocker that inhibits voltage-dependent calcium channels. dl-Tetrandrine selectively blocks Ca 2+ influx with an IC50 value of approximately 1-10 μM. dl-Tetrandrine exerts anti-inflammatory, immunosuppressive, and anti-arrhythmic activities by inhibiting intracellular calcium overload, and can reverse multidrug resistance in tumor cells. dl-Tetrandrine is promising for research of autoimmune diseases (such as rheumatoid arthritis), cardiovascular diseases, and tumor drug resistance reversal .
    dl-Tetrandrine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: